Michael Makris/LinkedIn
Feb 25, 2026, 16:34
Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”IMPORTANT.
Biomarin has decided to withdraw Roctavian, the only approved Haemophilia A gene therapy, from the market.
Biomarin announced several months ago that it wanted to sell Roctavian to another company, but since they failed to find a buyer, they made the decision to voluntarily withdraw Roctavian from the market.
The problem was not that this did not work, but rather that there are a lot of other highly effective choices for haemophilia A subjects available.”
Stay updated with Hemostasis Today.
-
Jul 19, 2026, 04:23Iris van Moort: Expert Insights on Pediatric Hemostasis Diagnostics at ISTH 2026
-
Jul 19, 2026, 04:09Er. Subodh Grewal: How Platelet Histograms Support Hematology Diagnosis
-
Jul 19, 2026, 03:53Serhii Pelishenko: Current Evidence on Kaolin and Chitosan Dressings
-
Jul 18, 2026, 23:52Chinua Onyebuchi: Applications Now Open for the European Stroke Master Programme
-
Jul 18, 2026, 22:43Exploring the Ultra-Late Window for Stroke Treatment – International Journal of Stroke
-
Jul 18, 2026, 21:38Swastik Sharma Deviprasad Bhat: A One-Minute Guide to Recognizing Stroke
-
Jul 18, 2026, 21:05Federica Fedele: From One-Size-Fits-All to Personalized Care
-
Jul 18, 2026, 21:04Sandra RodrÃguez Coma: A Great Experience With the Werfen Team at ISTH 2026
-
Jul 18, 2026, 20:58Heghine Khachatryan: Cancer-Associated ATE – An Underrecognized Challenge in Modern Oncology